2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

9:00AM-11:00AM: Abstract Number: 2676

Cardiovascular Treatment and the Incidence of Giant Cell Arteritis (GCA) – a Population-Based Case-Control Study

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2411

Casting a Wide Net: Comparing Strategies for Recruiting 18-35-year-olds with Rheumatic Disease as Study Participants

Research Methodology Poster – ARP

9:00AM-11:00AM: Abstract Number: 2258

Causes of Influenza Vaccine Hesitancy in Rheumatoid Arthritis and Adults with Juvenile Idiopathic Arthritis

Patient Outcomes, Preferences, & Attitudes Poster II: Patient Preferences, Beliefs, & Experiences

9:00AM-11:00AM: Abstract Number: 1987

CCN3 Regulates Macrophage Function in MSU-induced Inflammation

Osteoarthritis & Joint Biology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 1971

CD39 Produced from Human Gingiva-Derived Mesenchymal Stem Cells Regulates the Balance of Osteoclasts and Osteoblasts Through Wnt / β-catenin Pathway in Osteoporosis

Osteoarthritis & Joint Biology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 2626

Cell-free Mitochondrial DNA Levels in Granulomatosis with Polyangiitis

Vasculitis – ANCA-Associated Poster I

9:00AM-11:00AM: Abstract Number: 2519

Cenerimod, a Potent, Selective and Orally Active Sphingosine 1-phosphate Receptor 1 Modulator, Reduced Blood Antibody-secreting Cells in Patients with SLE

SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2602

Changes in Fecal Microbiota Composition After Fecal Microbiota Transplantation in Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 2399

Changes in the Initial Usage Pattern of Biologic Disease-modifying Antirheumatic Drugs in Rheumatic Diseases During the past Twelve Years: A Real-world Setting Analysis

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 2632

Changing Trends in the Management of ANCA-associated Vasculitis at an Academic Medical Center

Vasculitis – ANCA-Associated Poster I

9:00AM-11:00AM: Abstract Number: 2162

Characteristics of Patients with Rheumatoid Arthritis Undergoing Primary Total Joint Replacement: A 14-year Trend Analysis (2004-2017)

Orthopedics, Low Back Pain, & Rehabilitation Poster – ACR/ARP

9:00AM-11:00AM: Abstract Number: 2447

Characteristics of Psoriasis Patients with Subclinical Signs of Musculoskeletal Involvement Detected by Fluorescence Optical Imaging and Confirmed by MRI-assessment

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 1926

Characterization of DOCK8 as a Novel Gene Associated with Macrophage Activation Syndrome

Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 1956

Characterizing Arthritis Related to Immune Checkpoint Inhibitors Using Synovial Fluid and Matched Blood

Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 2157

Checkpoint Inhibitor-Associated Arthritis: Phenotype, Steroid Dose, Serology and Survival

Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies

«Previous Page
1
…
8
9
10
11
12
…
64
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].